Table 2. Emerging bispecific antibodies... | American Society of Hematology

Table 2.

Emerging bispecific antibodies

Characteristic	Epcoritamab²¹	Glofitamab²⁰	Mosunetuzumab²³	Odronextamab²²
Overall cohort
Sample size	157	155	129	49^*
ORR, %	63	52	34.9	39^*
CR, %	39	39	19.4	24^*
DOR, mo	12	18.4	7.6	4.4^*
PFS, mo	4.4	4.9	1.4	11.5
Follow-up, mo	10.7	12.6	11.9	4.2
Post–CAR T-cell cohort
Sample size	61	52	19	33
ORR, %	54	Not reported	37	33
CR, %	34	35	26	24
DOR (mos)	9.7	Not reported	Not reported	Not reached

Characteristic	Epcoritamab²¹	Glofitamab²⁰	Mosunetuzumab²³	Odronextamab²²
Overall cohort
Sample size	157	155	129	49^*
ORR, %	63	52	34.9	39^*
CR, %	39	39	19.4	24^*
DOR, mo	12	18.4	7.6	4.4^*
PFS, mo	4.4	4.9	1.4	11.5
Follow-up, mo	10.7	12.6	11.9	4.2
Post–CAR T-cell cohort
Sample size	61	52	19	33
ORR, %	54	Not reported	37	33
CR, %	34	35	26	24
DOR (mos)	9.7	Not reported	Not reported	Not reached

^*

Responses reported are for patients with DLBCL without prior CAR T-cell therapy.